Peptide Companion
Peptide Companion
blend
Anti-Aging
Vial: 48 mg

How is Neuroxelin (48 mg Vial) dosed and mixed?

Neuroxelin (48 mg Vial) is a peptide blend research reference in the Anti-Aging category for a 48 mg vial. The reference mixing guide adds 3 mL of bacteriostatic water, giving a concentration of 16 mg/mL. The full reference schedule, supplies and cited studies are listed below; it is reference information, not a recommendation.

By Vincent Ceniceros · Published · Last updated

Neuroxelin dosage protocols are designed to support neuroprotection and cognitive recovery following brain injury or stroke. As a synthetic neuroprotective peptide, Neuroxelin may help reduce excitotoxic damage, modulate neuroinflammation, and support neural repair processes. Research suggests that Neuroxelin-class peptides can promote improved neurological outcomes and cognitive function when administered consistently over several weeks. This educational protocol outlines a once-daily subcutaneous approach optimized for sustained neuroprotective coverage.

Detailed protocol below.

Dosing Schedule
WeekDaily Dose (mcg)Units (per injection) (mL)
Weeks 1–4500 mcg3 units (0.03 mL)
Weeks 5–8750 mcg4.7 units (0.047 mL)
Mixing & Quick Reference
Bacteriostatic water
3 mL
Concentration
16 mg/mL
  • •Reconstitute: Add 3.0 mL bacteriostatic water → 16 mg/mL concentration.
  • •Typical daily range: 250–1000 mcg once daily (standard dose: 500 mcg).
  • •Easy measuring: At 16 mg/mL, 1 unit = 0.01 mL = 160 mcg on a U-100 insulin syringe.
  • •Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Supplies Needed
  • •Peptide Vials (Neuroxelin, 48 mg each):
  • •Insulin Syringes (U-100, 30- or 50-unit recommended):
  • •Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Benefits
  • •Research suggests improved neurological outcomes and functional recovery following stroke or brain injury.
  • •Studies of peptide supplementation show significant improvements in cognitive test scores (MoCA) and information processing speed over 90–360 days.
  • •Animal studies demonstrate reduced neuronal death, decreased microglial activation, and better behavioral outcomes.
  • •Related peptides show low toxicity profiles with no significant difference in adverse events versus placebo in Phase III trials.
  • •Possible mild injection-site reactions (redness, irritation) may occur with subcutaneous administration; rotate sites to minimize.
How It Works

Neuroxelin is designed to intervene in the cascade of brain injury through multiple mechanisms. It may dampen excitotoxic neuron death by disrupting NMDA receptor signaling pathways, similar to nerinetide (NA-1), which interferes with PSD-95 protein interactions. Additionally, Neuroxelin-class peptides can reduce neuroinflammation by downregulating microglial activation and cytokine release, as demonstrated in studies of apoE-mimetic peptides like CN-105. The peptide may also provide neurotrophic support by promoting synaptic repair and neurogenesis, supporting neuronal survival and vascular repair following acute brain injuries.

References and original studies

  • The Lancet

    Efficacy and safety of nerinetide for acute ischaemic stroke (ESCAPE-NA1): Phase 3 RCT of PSD-95 inhibitor peptide

    View source

  • Scientific Reports (Nature)

    Neuroprotective pentapeptide CN-105 reduces sterile inflammation and improves outcomes in TBI murine model

    View source

  • Drugs (Springer/PubMed)

    Efficacy and safety of sovateltide in acute cerebral ischaemic stroke: Phase III clinical trial

    View original study

  • Nutrients (PMC)

    Neuropsychological performance after extended N-Pep-12 supplementation in ischemic stroke (12-month study)

    View original study

  • GenScript

    Peptide storage and handling guidelines: stability, reconstitution, and freeze-thaw considerations

    View source

  • NIBSC (UK MHRA)

    Peptide handling, dissolution, and storage guidelines from standards agency

    View source

  • Biochimica et Biophysica Acta (ScienceDirect)

    Advances in clinical studies of peptide drugs in stroke disease: mechanisms and progress

    View source

  • Stroke (AHA Journals)

    Factors influencing nerinetide effect on infarct volume in stroke patients

    View original study

  • PubMed

    Phase 1 randomized, double-blind, placebo-controlled study of CN-105 safety and pharmacokinetics

    View original study

  • CDC

    Vaccine administration: subcutaneous injection technique (angle, site, no aspiration)

    View source

  • CDC

    Vaccine administration during vaccination: subcutaneous injection guidance

    View source

  • Advances in Therapy (PMC)

    Subcutaneous injection of drugs: factors influencing pain sensation at injection site

    View original study

  • Translational Psychiatry (Nature)

    Davunetide effects on memory in prodromal Alzheimer’s disease

    View source

  • Schizophrenia Research (ScienceDirect)

    Effect of the neuroprotective peptide davunetide (AL-108) on cognition and safety

    View source

About the author

Vincent Ceniceros

Vincent Ceniceros created Peptide Companion and publishes its Dosage Library. Each guide summarizes a reference protocol and links to the studies and sources it draws on.

Published · Last updated

Related guides

Work out the mixing math for any vial with the peptide reconstitution calculator, or browse the full Dosage Library.

Educational content adapted from peptidedosages.com. Not medical advice.